Alluvi, previously BI 4744, presents a significant advance in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling efficacy in clinical https://alluvi-retatrutide890394.wikipublicity.com/user